Patents Assigned to GENETOLEAD INC.
  • Publication number: 20240408064
    Abstract: There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS.
    Type: Application
    Filed: October 14, 2022
    Publication date: December 12, 2024
    Applicant: GENETOLEAD INC.
    Inventors: Luc FARMER, Steven LAPLANTE, Yann AYOTTE, Sacha Thierry LARDA, Saba ALAPOUR, Simon WOO, David BENDAHAN, Maria DENK, Majid FARAHANI, Mustapha IDDIR